GleamWall
中文EN

VRDN Viridian Therapeutics, Inc.\DE

Pharmaceutical Preparations · Nasdaq · SEC CIK 1590750 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-62.8%
TTM net income YoY-50.2%
TTM EPS YoY—
Revenue 3-yr CAGR323.2%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-1,781.4%
Net margin-1,724.1%
FCF margin-1,305.4%
EBITDA margin-1,778.7%

Returns

ROE-83.7%
ROA-56.5%
ROIC (approx.)-97.2%
Asset turnover0.03x

Leverage & solvency

Liabilities / assets43.5%
Debt / equity0.00x
Current ratio14.46x
Interest coverage-19.27x

Cash quality & payout

Operating cash flow / net income0.75x
Accruals ratio-14.0%
Payout ratio—
Capex / revenue7.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$70.85M$302,000
R&D expense$338.93M$238.25M
SG&A expense$95.31M$61.08M
Operating income-$363.39M-$299.04M
Interest expense$4.95M$2.20M
Income tax$0—
Net income-$342.60M-$269.95M
EBITDA-$362.94M-$298.50M
EPS (diluted)——
Balance sheet
Cash & equivalents$212.38M$99.59M
Short-term investments$662.27M$617.99M
Receivables$0—
Inventory$0—
Current assets$894.23M$738.46M
PP&E, net$1.23M$1.24M
Intangibles$0—
Total assets$899.42M$742.40M
Current liabilities$70.70M$47.87M
Short-term debt—$0
Long-term debt—$20.58M
Total debt—$20.58M
Total liabilities$177.25M$70.76M
Shareholders' equity$722.17M$671.64M
Net debt—-$79.01M
Shares outstanding101.83M80.99M
Cash flow statement
Operating cash flow-$276.39M-$232.32M
Capital expenditure$495,000$511,000
Free cash flow-$276.89M-$232.83M
Investing cash flow-$37.56M-$228.65M
Financing cash flow$426.74M$457.74M
Depreciation & amortization$460,000$540,000
Stock-based compensation$44.30M$42.15M

Free plan shows the latest 2 periods; Pro shows all 13 🔒

· This company does not report gross profit in XBRL.

· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.